NCT06756269View on ClinicalTrials.gov

To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

August 13, 2025

Study Completion Date

January 13, 2026

Conditions
HPV InfectionHPV-Related CarcinomaHPV-Related Intraepithelial NeoplasiaGenital Wart
Interventions
BIOLOGICAL

Medium dose for 15-HPV vaccine

Participants aged 9-45 years were given 3 doses of medium dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule

BIOLOGICAL

High dose for 15-HPV vaccine

Participants aged 9-45 years were given 3 doses of high dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule

BIOLOGICAL

Placebo

Participants aged 9-45 years were given 3 doses of placebo intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule

BIOLOGICAL

9-HPV vaccine

Participants aged 9-45 years were given 3 doses of 9-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule

Trial Locations (1)

530028

Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning

All Listed Sponsors
lead

Shanghai Bovax Biotechnology Co., Ltd.

INDUSTRY

NCT06756269 - To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years | Biotech Hunter | Biotech Hunter